Literature DB >> 15004061

Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method.

Claudio Scarparo1, Paolo Ricordi, Giuliana Ruggiero, Paola Piccoli.   

Abstract

The performance of the fully automated BACTEC MGIT 960 (M960) system for the testing of Mycobacterium tuberculosis susceptibility to streptomycin (SM), isoniazid (INH), rifampin (RMP), ethambutol (EMB), and pyrazinamide (PZA) was evaluated with 100 clinical isolates and compared to that of the radiometric BACTEC 460TB (B460) system. The agar proportion method and the B460 system were used as reference methods to resolve the discordant results for SM, INH, RMP, and EMB (a combination known as SIRE) and PZA, respectively. The overall agreements were 96.3% for SIRE and 92% for PZA. For SIRE, a total of 26 discrepancies were found and were resolved in favor of the M960 system in 8 cases and in favor of the B460 system in 18 cases. The M960 system produced 8 very major errors (VME) and 10 major errors (ME), while the B460 system showed 4 VME and 4 ME. No statistically significant differences were found. Both systems exhibited excellent performance, but a higher number of VME was observed with the M960 system at the critical concentrations of EMB and SM. For PZA, a total of eight discrepancies were observed and were resolved in favor of the M960 system in one case and in favor of the B460 system in seven cases; no statistically significant differences were found. The M960 system showed four VME and three ME. The mean times to report overall PZA results and resistant results were 8.2 and 9.8 days, respectively, for the M960 system and 7.4 and 8.1 days, respectively, for the B460 system. Statistically significant differences were found. The mean times to report SIRE results were 8.3 days for the M960 system and 8.2 days for the B460 system. No statistically significant differences were found. Twelve strains tested for SIRE susceptibility and seven strains tested for PZA susceptibility had been reprocessed because of contamination. In conclusion, the M960 system can represent a valid alternative to the B460 for M. tuberculosis susceptibility testing; however, the frequent contamination of the tests needs to be improved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004061      PMCID: PMC356895          DOI: 10.1128/JCM.42.3.1109-1114.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Reliability of the MB/BacT system for testing susceptibility of Mycobacterium tuberculosis complex isolates to antituberculous drugs.

Authors:  F Brunello; R Fontana
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Comparison of susceptibility testing of Mycobacterium tuberculosis using the ESP culture system II with that using the BACTEC method.

Authors:  P Ruiz; F J Zerolo; M J Casal
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

3.  Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the radiometric BACTEC 460TB method and the agar plate method of proportion.

Authors:  Enrico Tortoli; Marta Benedetti; Alessandra Fontanelli; M Tullia Simonetti
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

4.  Susceptibility testing with the manual mycobacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis.

Authors:  Kati Adjers-Koskela; Marja-Leena Katila
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  F Ardito; B Posteraro; M Sanguinetti; S Zanetti; G Fadda
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

6.  The resurgence of tuberculosis: is your laboratory ready?

Authors:  F C Tenover; J T Crawford; R E Huebner; L J Geiter; C R Horsburgh; R C Good
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

7.  Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system.

Authors:  Gaby E Pfyffer; Frantiska Palicova; Sabine Rüsch-Gerdes
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

8.  Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis.

Authors:  Pascale Bemer; Frantiska Palicova; Sabine Rüsch-Gerdes; Henri B Drugeon; Gaby E Pfyffer
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

9.  Multicenter evaluation of the mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs.

Authors:  S Rüsch-Gerdes; C Domehl; G Nardi; M R Gismondo; H M Welscher; G E Pfyffer
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

10.  Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

Authors:  M Salfinger; L B Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

  10 in total
  44 in total

1.  Evaluation of the VersaTREK system compared to the Bactec MGIT 960 system for first-line drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  M Espasa; M Salvadó; E Vicente; G Tudó; F Alcaide; P Coll; N Martin-Casabona; M Torra; D Fontanals; J González-Martín
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

Review 2.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

3.  Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  Niuris C Mirabal; Sergio L Yzquierdo; Dihadenys Lemus; Mariela Madruga; Yoslaine Milián; Miguel Echemendía; Howard Takiff; Anandi Martin; Patrick Van der Stuyf; Juan Carlos Palomino; Ernesto Montoro
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

4.  Verification of antimicrobial susceptibility testing of Mycobacterium tuberculosis.

Authors:  Leslie Hall; Kelly A Doerr; W Scott Harmsen; Nancy L Wengenack; Glenn D Roberts
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

Review 5.  Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems.

Authors:  Claudio Piersimoni; Armando Olivieri; Luca Benacchio; Claudio Scarparo
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

6.  Does the MGIT 960 system improve the turnaround times for growth detection and susceptibility testing of the Mycobacterium tuberculosis complex?

Authors:  Akos Somoskovi; Anne Clobridge; Susan C Larsen; Oleg Sinyavskiy; Suheyla Surucuoglu; Linda M Parsons; Max Salfinger
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

7.  Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.

Authors:  Sabine Rüsch-Gerdes; Gaby E Pfyffer; Manuel Casal; Maureen Chadwick; Salman Siddiqi
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

8.  Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis.

Authors:  Annika Krüüner; Malcolm D Yates; Francis A Drobniewski
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

9.  Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.

Authors:  Stellah G Mpagama; Norah Ndusilo; Suzanne Stroup; Happiness Kumburu; Charles A Peloquin; Jean Gratz; Eric R Houpt; Gibson S Kibiki; Scott K Heysell
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

10.  Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan.

Authors:  Chiyoji Abe; Ikuo Kobayashi; Satoshi Mitarai; Masako Wada; Yoshiko Kawabe; Tetsuya Takashima; Katsuhiro Suzuki; Li-Hwei Sng; Suxing Wang; Hla Hla Htay; Hideo Ogata
Journal:  J Clin Microbiol       Date:  2008-05-28       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.